| Literature DB >> 30937168 |
Getachew Arage1, Mekonnen Assefa2, Teshager Worku3, Agumasie Semahegn3.
Abstract
OBJECTIVE: To determine the survival rate and predictors of HIV-infected children on antiretroviral therapy at two selected facilities in North Ethiopia.Entities:
Keywords: Ethiopia; HIV-infected children; anti-retroviral therapy; cohort; survival
Year: 2019 PMID: 30937168 PMCID: PMC6434434 DOI: 10.1177/2050312119838957
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Figure 1.Schematic presentation of study participants’ recruitment and allocation process.
Socio-demographic characteristics of study participants on ART at two selected hospitals, 1 December 2005–31 November 2015 (n = 426).
| Characteristics | n | % | |
|---|---|---|---|
| Sex of the caregiver | Female | 341 | 80.1 |
| Male | 85 | 19.9 | |
| Age caregivers in year | <20 | 21 | 4.9 |
| 20–35 | 248 | 50.7 | |
| >35 | 155 | 36.4 | |
| Place of residence | Urban | 334 | 78.4 |
| Rural | 92 | 21.6 | |
| Marital status of the caregivers | Single | 80 | 18.7 |
| Married | 280 | 3.6 | |
| Divorced | 48 | 6.6 | |
| Widowed | 28 | 0.5 | |
| Religion | Orthodox | 253 | 59.4 |
| Muslim | 171 | 40.1 | |
| Protestant | 2 | 0.5 | |
| Educational status | Can’t read and write | 169 | 39.6 |
| primary school (1–8) | 162 | 38.0 | |
| Secondary school and above | 46 | 10.8 | |
| More than 12 and above | 49 | 11.5 | |
| Ethnicity | Amhara | 417 | 97.9 |
| Tigray | 8 | 1.9 | |
| Others | 1 | 0.2 | |
| Occupation | Merchant | 60 | 14.9 |
| Housewife | 204 | 47.9 | |
| Farmer | 44 | 10.3 | |
| Government employee | 76 | 17.8 | |
| Others[ | 42 | 9.9 | |
| Sex of the child | Male | 209 | 49.1 |
| Female | 217 | 50.9 | |
| HIV disclosure status | Yes | 196 | 46.0 |
| No | 230 | 54.0 | |
| Age at start of the ART | ⩾24 months | 51 | 12.0 |
| 25–59 months | 81 | 19.0 | |
| 60–121 months | 218 | 51.2 | |
| ⩾122 months | 76 | 17.8 |
Others: students, daily labor.
Clinical and immunological status of children on ART at two selected hospitals, Northern Ethiopia, 1 December 2005–31 November 2015.
| Characteristics | n | % | |
|---|---|---|---|
| Baseline WHO clinical stage (n = 426) | Stage I | 105 | 24.6 |
| Stage II | 139 | 32.6 | |
| Stage III | 156 | 36.6 | |
| Stage IV | 26 | 6.1 | |
| Endline WHO clinical stage (n = 418) | Stage I (TI) and II (TII) | 399 | 93.7 |
| Stage (TIII) and TIV | 19 | 4.5 | |
| Baseline CD4 count, cells/mm3 (n = 419) | >200 | 271 | 64.7 |
| ⩽200 | 148 | 35.3 | |
| Endline CD4 count (n = 413) | >200 | 46 | 11.1 |
| ⩽200 | 367 | 88.9 | |
| Disclosure HIV status | Yes | 196 | 46.0 |
| No | 230 | 54.0 | |
| Nutritional status (n = 314) | Mild malnutrition | 73 | 17.1 |
| Moderate malnutrition | 208 | 48.8 | |
| Severe malnutrition | 33 | 7.7 | |
| OIs during follow-up | Yes | 240 | 56.3 |
| No | 186 | 43.7 | |
| Cotrimoxazole preventive therapy | Yes | 357 | 83.8 |
| No | 69 | 16.2 | |
| Hemoglobin level (n = 407) | <10 mg/dL | 183 | 45.0 |
| ⩾10 mg/dL | 224 | 55.0 | |
| Adherence to ART (n = 421) | Good | 356 | 84.5 |
| Poor | 65 | 15.4 | |
| Psychosocial support (n = 413) | Yes | 154 | 37.2 |
| No | 259 | 62.3 | |
| Developmental milestone | Appropriate | 362 | 84.9 |
| Delayed | 60 | 14.1 | |
| Regressing | 4 | 0.9 | |
| Follow-up status | Alive | 325 | 77.0 |
| Dead | 97 | 23.0 |
OIs: opportunistic infections; TI: treatment stage I; TII: treatment stage II; TIII: treatment stage III; WHO: World Health Organization; ART: antiretroviral therapy.
Figure 2.Kaplan-Meier survival curve among children on ART at Debre Tabor General Hospital and Dessie referral hospital, 1 January 2005–31 March 2015.
Bivariate and multivariate Cox regression analysis of HIV-infected children on ART 1 December 2005–31 November 2015.
| Characteristics | Survival status | Row total | CHR (95% CI) | AHR (95% CI) | ||
|---|---|---|---|---|---|---|
| Alive | Dead | |||||
| Sex | Male | 157 | 52 | 209 | 1.0 (Ref.) | |
| Female | 168 | 45 | 213 | 1.09 (0.01–2.4) | ||
| Age | <24 months | 35 | 16 | 51 | 1.0 (Ref.) | |
| 25–59 months | 60 | 21 | 81 | 1.1 (0.5–2.2) | ||
| 60–121 months | 172 | 45 | 217 | 1.1 (0.6–2.2) | ||
| >122 months | 58 | 15 | 73 | 1.0 (0.6–1.8) | ||
| HIV disclosure status | Yes | 139 | 48 | 187 | 1.0 (Ref.) | |
| No | 186 | 49 | 235 | 1.3 (0.2–9.4) | ||
| Presence of OIs | Yes | 183 | 56 | 239 | 1.0 (Ref.) | |
| No | 142 | 41 | 183 | 2.5 (0.01–4.6) | ||
| Current WHO clinical stages | Stages I and II | 304 | 93 | 397 | 1.2 (0.4–3.3) | |
| Stages III and IV | 23 | 4 | 27 | 1.0 (Ref.) | ||
| Baseline Nutritional status | Mild malnutrition | 81 | 63 | 144 | 1.0 (Ref.) | 1.0 (Ref.) |
| Moderate malnutrition | 182 | 72 | 254 | 2.1 (0.9–3.7) | 1.8 (0.9–3.6) | |
| Severe malnutrition | 62 | 12 | 74 | 1.9 (0.9–4.9) | 2.5 (1.1–6.1) | |
| Taking CPT | Yes | 268 | 83 | 351 | 1.0 (Ref.) | |
| No | 57 | 14 | 71 | 1.2 (0.01–1.4) | ||
| Hemoglobin level | <10 mg/dL | 138 | 45 | 183 | 1.0 (0.8, 1.2) | |
| ⩾10 mg/dL | 171 | 53 | 224 | 1.0 (Ref.) | ||
| Adherence level | Good | 274 | 82 | 356 | 1.0 (Ref.) | |
| Poor | 51 | 15 | 66 | 0.2 (0.1–0.4) | 3.0 (1.2–7.5) | |
| Psychosocial support | Yes | 130 | 36 | 166 | 1.1 (1.1.–1.8) | 0.3 (0.1–0.7) |
| No | 195 | 61 | 256 | 1.0 (Ref.) | 1.0 (Ref.) | |
| Baseline CD4 count | >200 | 214 | 55 | 269 | 0.5 (0.3–0.8) | 0.7 (0.4–0.9) |
| ⩽200 | 102 | 42 | 144 | 1.0 (Ref.) | 1.0 (Ref.) | |
OIs: opportunistic infections; CPT: cotrimoxazole preventive therapy; HR: hazard ratio; CHR: crude hazard ratio; AHR: adjusted hazard ratio; Ref.: reference; WHO: World Health Organization.
p-value ⩽ 0.05.